Not Yet RecruitingNot Applicable

Impact of Enoxaparin Therapy on Fetal Outcomes in Intrauterine Growth Restriction

Pakistan108 participantsStarted 2026-04-01

Plain-language summary

The local literature lacks comprehensive information regarding the actual incidence of intrauterine growth restriction (IUGR) and oligohydramnios and currently available therapeutic options. Therefore, the current study was planned with the objective to evaluate the impact of enoxaparin therapy compared with standard management on neonatal outcomes in pregnancies complicated by intrauterine growth restriction (IUGR) with oligohydramnios.

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women aged 18-40 years * Singleton pregnancy * Gestational age ≥28 weeks (confirmed by first-trimester scan or reliable last menstrual period) * Diagnosed with both IUGR and oligohydramnios * Willing to provide informed written consent Exclusion Criteria: * Multiple gestation * Major fetal congenital anomalies * Maternal medical disorders affecting pregnancy outcome (e.g., uncontrolled diabetes, chronic hypertension, renal disease) * Known coagulation disorders or contraindications to enoxaparin * Women already on anticoagulation therapy.

What they're measuring

Live birth

Timeframe: 12 weeks

Low Birth weight

Timeframe: 12 weeks

Trial details

NCT IDNCT07462182

SponsorMuhammad Aamir Latif

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-30

Contact for this trial

Maimoona Hafeez

+923135495729 maimoonahafeez777@gmail.com

View on ClinicalTrials.gov More Intrauterine Growth Restriction trials